



# ACTAS Dermo-Sifiliográficas

Full English text available at  
[www.actasdermo.org](http://www.actasdermo.org)



## BRIEF COMMUNICATION

### [Translated article] Analyzing the Quality of Life of Individuals With Cutaneous Lymphomas

A. Sánchez-Merino<sup>a</sup>, F. Vílchez-Márquez <sup>b,c,\*</sup>, A. Núñez-García<sup>d</sup>,  
C. Botella-García<sup>d</sup>, S. Arias-Santiago<sup>b,c,e</sup>

<sup>a</sup> Facultad de Medicina, Universidad de Granada, Granada, Spain

<sup>b</sup> Servicio de Dermatología, Hospital Universitario Virgen de las Nieves, Granada, Spain

<sup>c</sup> Instituto de investigación biosanitaria ibs.GRANADA, Granada, Spain

<sup>d</sup> Servicio de Hematología. Hospital Universitario Virgen de las Nieves, Granada, Spain

<sup>e</sup> Departamento de Dermatología, Facultad de Medicina, Universidad de Granada, Granada, Spain

Received 23 June 2024; accepted 25 August 2024

#### KEYWORDS

Primary cutaneous lymphomas;  
Quality of life;  
Quality of life questionnaires;  
Health-related quality of life

#### PALABRAS CLAVE

Linfomas cutáneos primarios;  
Calidad de vida;  
Cuestionarios de calidad de vida;  
Calidad de vida relacionada con la salud

**Abstract** Primary cutaneous lymphomas are a heterogeneous group of non-Hodgkin's lymphomas, most of them chronic with multiple relapses, which can have an impact on the patient's quality of life. The main aim of the study was to assess the quality of life of patients with cutaneous lymphomas using different validated questionnaires. A total of 32 patients were included in the study (mean age, 64 years; 75% men). A total of 68.8% of lymphomas were mycosis fungoïdes. Age, number of therapies administered and pruritus were associated with worse quality of life as assessed by the different questionnaires. The use of quality of life-questionnaires may be useful in the holistic evaluation of the patient.

© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

#### Análisis de la calidad de vida en los pacientes con linfomas cutáneos

**Resumen** Los linfomas cutáneos primarios son un grupo heterogéneo de linfomas de tipo no Hodgkin, la mayoría de carácter crónico con múltiples recaídas, que pueden provocar una repercusión en la calidad de vida. El objetivo principal del estudio fue evaluar la calidad de vida de los pacientes con linfomas cutáneos mediante el empleo de diferentes cuestionarios validados. Se incluyeron 32 pacientes en el estudio, con una edad media de 64 años, siendo el 75% varones y el 68,8% de los linfomas de tipo micosis fungoide. La edad, el número de tratamientos empleados y el prurito se asociaron a una peor calidad de vida, evaluada por los diferentes

DOI of original article: <https://doi.org/10.1016/j.ad.2024.08.015>

\* Corresponding author.

E-mail address: [fvilchezm@hotmail.com](mailto:fvilchezm@hotmail.com) (F. Vílchez-Márquez).

<https://doi.org/10.1016/j.ad.2025.07.014>

0001-7310/© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

cuestionarios. El empleo de cuestionarios de calidad de vida puede ser útil en la evaluación holística del paciente.

© 2025 AEDV. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Primary cutaneous lymphomas (PCLs) represent a heterogeneous group of non-Hodgkin lymphomas whose first clinical manifestation occurs in the skin without evidence of extracutaneous involvement at the time of diagnosis.<sup>1</sup> A total of 75–80% of PCLs are cutaneous T-cell lymphomas (CTCLs), and the remaining 20–25%, cutaneous B-cell lymphomas (CBCLs).<sup>2</sup> Of all these, mycosis fungoides (MF) is the most frequent form, which, along with Sézary syndrome (SS), accounts for almost half of all PCLs.<sup>3</sup>

Currently, there is no curative treatment, so most PCLs run a chronic course with multiple relapses. Furthermore, the visibility of the lesions along with skin involvement such as itching, desquamation, and pain can significantly impact the patients' quality of life (QOL).<sup>4,5</sup> In PCLs, the use of questionnaires to assess QOL has been poorly studied, with existing studies focusing on CTCLs.<sup>6–12</sup> Therefore, we initiated this study with the primary endpoint of evaluating QOL in patients with PCLs. Secondarily, we aimed to explore factors associated with poorer QOL and compare QOL between patients with MF, as it is the most frequent type, and other PCLs.

## Patients and methods

We conducted a cross-sectional study with patients diagnosed with any type of PCL, regardless of their severity and treatment level on therapy at the Cutaneous Lymphoma Unit of Hospital Universitario Virgen de las Nieves. The patient inclusion period for the study went from February to May 2024.

Demographic and clinical data (age, sex, type of lymphoma, duration of evolution, etc.) were collected, and the various study questionnaires were completed. Questionnaires related to disease severity were the Modified Severity-Weighted Assessment Tool (mSWAT) and the Itch Severity Scale (ISS). Questionnaires to evaluate quality of life and well-being were Skindex-29, the Dermatology Life Quality Index (DLQI), the Hospital Anxiety and Depression Scale (HADS), and the WHO-5 Well-Being Index questionnaire.

All statistical analyses were performed with the SPSS® package (SPSS for Mac, Version 21.0 Chicago: SPSS Inc.).

## Results

A total of 32 patients with PCLs were included in the study, with a mean course of the disease of  $79.31 \pm 79.02$  months. The clinical/epidemiological characteristics studied are shown in Table 1.

Bivariate analysis was performed to identify factors associated with a poorer quality of life (Table 2). Older age was associated with a higher DLQI score ( $p=0.039$ ). A higher Skindex-29 score was found in patients with a greater number of previous treatments ( $p=0.035$ ). Finally, the presence of pruritus was statistically significantly associated with higher scores on Skindex-29 ( $p<0.001$ ), DLQI ( $p<0.001$ ), WHO-5 ( $p=0.003$ ), and HADS, in both the anxiety ( $p=0.007$ ) and the depression subscales ( $p=0.010$ ). No statistically significant findings were found for the rest of the variables.

Bivariate analysis was performed to compare quality of life between patients with MF, as it is the most frequent type, and other PCLs. The prevalence of pruritus in patients with mycosis fungoides was 75%, while in the group of other cutaneous lymphomas it was 41.7%; of the total patients with pruritus, only 1 had B-cell lymphoma, being the remaining 19 T-cell lymphomas. Nonetheless, no statistically significant differences were found. No statistically significant differences were found either between MF and other PCLs in the different quality of life questionnaires used.

Finally, the relationship between Skindex-29 and ISS scores was analyzed using linear regression (Fig. 1). It was observed that for every increase in the ISS score, Skindex-29 increased by 1.14 points ( $p<0.001$ ;  $R=0.721$ ).

## Discussion

In this study, several factors associated with a poorer quality of life in patients with PCLs were found, such as age, the number of previous treatments received, or the presence of pruritus. The variety of questionnaires used in the literature to assess QOL in PCL patients complicates the comparison of obtained data, in addition to the fact that most studies focus on QOL in CTCL patients,<sup>6–14</sup> with very few including all types of PCLs.<sup>5,15,16</sup> Despite this, we observed that older patients had a higher DLQI score, and thus a greater impact on their QOL, which is consistent with former studies.<sup>5,6,16</sup> Other factors classically associated with poorer QOL in PCL patients such as female sex, Black patients, advanced disease stages, SS, psychiatric comorbidity, or type of treatment<sup>4,7</sup> were not found in our study, probably due to the inclusion of all PCL types (not just MF/SS); the small sample size; and the absence of patients with SS or from different ethnic/racial groups.

On the other hand, the study found more cases of severe Skindex-29 in patients with >2 previous treatments. It has been reported that treatment with corticosteroids or interferon is associated with a poorer QOL,<sup>5</sup> mainly due to its association with anxiety and depression. However, the association between the number of previous treatments and severe cases in Skindex-29 has not been described in the lit-

**Table 1** Sociodemographic and clinical characteristics of the sample (*n*=32).

Variable	Number (%) or mean ± SD
Age (years)	64.19 ± 15.28
Sex	Male: 24 (75%) Female: 8 (25%)
Type of PCL	Mycosis fungoides: 22 (68.8%) Primary cutaneous marginal zone B-cell lymphoma: 3 (9.4%) Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: 2 (6.3%) Lymphomatoid papulosis: 2 (6.3%) Large-cell PCL lymphoma: 2 (6.3%) Follicle center CTCL: 1 (3.1%)
Stage (MF, <i>n</i> =22)	IA: 11 (50%) IB: 5 (22.7%) IIA: 1 (4.5%) IIIA: 2 (9.1%) IVA: 1 (4.5%) IVB: 2 (9.1%)
Stage (non-MF, <i>n</i> =10)	T1aN0M0: 5 (50%) T2bN0M0: 1 (10%) T2cN0M0: 1 (10%) T3aN0M0: 2 (20%) T3bN0M0: 1 (10%) MF: 46.61 ± 37.77 Non-MF: 35.89 ± 32.57
Follow-up time (months)	1.97 ± 1.4
Number of treatments	19.59 ± 38.42
mSWAT (MF, <i>n</i> =22)	6 ± 5.97
ISS	33.12 ± 11.71
Skindex-29	4.03 ± 4.74
DLQI	Anxiety: 3.66 ± 4.42
HADS	Depression: 2.34 ± 3.58
WHO-5	20.31 ± 5.46

SD, standard deviation; DLQI, Dermatology Life Quality Index; HADS, Hospital Anxiety and Depression Scale; ISS, Itch Severity Scale; CTCL, cutaneous T-cell lymphoma; PCL, primary cutaneous lymphomas; MF, mycosis fungoides; mSWAT, Modified Severity-Weighted Assessment Tool.

erature to this date. This association can be interpreted as patients who have been treated with >2 treatments having a worse QOL, since for them the use of different therapeutic measures has not been effective, and therefore their impairment is greater as clinical control of the disease has not been achieved. This is, therefore, an important piece of data to consider in the clinical and therapeutic management of these patients.

Although our study found no association between QOL and HADS, the results show that probably up to 5 patients could have been diagnosed with anxiety, and up to 2 with depression. This fact is of great importance, as numerous studies emphasize the impact on PCL patients not only physically, but also emotionally, economically, and functionally, which negatively influences their QOL.<sup>9-11</sup> A recently published study shows the cost of treatment and care for PCL patients in Spain,<sup>17</sup> reflecting the economic component of the disease, especially in countries where patients bear the costs.

The main finding of our study is that the presence of pruritus is associated with higher scores on Skindex-29, DLQI,

WHO-5, and HADS, in both the anxiety and depression subscales. Furthermore, a positive association was observed between ISS and Skindex-29 values. Pruritus was therefore the most debilitating symptom and the one most associated with a decrease in QOL as measured by the different questionnaires in the study, which is consistent with current studies,<sup>4,5,18</sup> where pruritus is described by patients as the most frequent symptom and the one that most affected their daily lives, interfering with sleep and being associated with a great impact on QOL. This symptom is common in PCLs, but it is more frequent in CTCLs, where worsening pruritus is associated with disease progression, relapse, or infection, making its therapeutic management especially important to improve patients' QOL.<sup>19</sup> In accordance with published literature, in our study, pruritus affected CTCL patients more, with only 1 patient with CBCL complaining of this symptom, so in this group, the impact on their QOL could be due to different causes.

Finally, no differences in QOL were found between MF and other PCLs across the different questionnaires used. We

A. Sánchez-Merino, F. Vílchez-Márquez, A. Núñez-García et al.

**Table 2** Analysis of factors associated with higher scores in Skindex-29, DLQI, HADS, and WHO-5.

Variable	Skindex-29 mild/moderate	Skindex-29 severe	p-Value	DLQI no impairment	DLQI impairment	p-Value			
<i>Age</i>	27 (84.37%)	5 (15.6%)	0.325	29 (90.62%)	3 (9.4%)	0.039			
<i>Sex</i>									
Male	21 (65.62%)	3 (9.4%)	0.367	22 (68.75%)	2 (6.3%)	0.592			
Female	6 (18.75%)	2 (6.3%)		7 (21.87%)	1 (3.1%)				
<i>Course of the disease</i>	27 (84.37%)	5 (15.6%)	0.949	29 (90.62%)	3 (9.4%)	0.718			
<i>Number of treatments</i>									
≤2	23 (71.87%)	3 (9.4%)	0.035	24 (75%)	2 (6.3%)	0.127			
>2	4 (12.5%)	2 (6.3%)		5 (15.62%)	1 (3.1%)				
<i>MF stage</i>									
<IIIB	14 (43.75%)	3 (9.4%)	0.675	15 (46.87%)	2 (6.3%)	0.558			
≥IIIB	4 (12.5%)	1 (3.1%)		4 (12.5%)	1 (3.1%)				
<i>mSWAT (MF)</i>	18 (81.81%)	4 (18.2%)	0.118	19 (86.36%)	3 (13.6%)	0.132			
<i>Pruritus</i>									
Yes	15 (46.87%)	5 (15.6%)	< 0.001	17 (53.12%)	3 (13.6%)	< 0.001			
No	12 (37.5%)	0		12 (37.5%)	0				
Variables	HADS		p-value	WHO-5		p-value			
	Anxiety (A)	Depression (D)		No impairment (>13)	No impairment (≤13)				
<i>Age</i>	<10 27 (84.3%)	≥10 5 (15.6%)	<10 30 (93.7%)	≥10 2 (6.3%)	A 0.195	D 0.554	28 (87.5%)	4 (12.5%)	0.271
<i>Sex</i>									
Male	22 (68.7%)	2 (6.3%)	23 (71.8%)	1 (3.1%)	0.085	0.444	21 (65.6%)	3 (9.4%)	0.746
Female	5 (15.6%)	3 (9.4%)	7 (21.8%)	1 (3.1%)			7 (21.8%)	1 (3.1%)	
<i>Course of the disease</i>	27 (84.3%)	5 (15.6%)	30 (93.7%)	2 (6.3%)	0.798	0.661	28 (87.5%)	4 (12.5%)	0.570
<i>Number of treatments received</i>									
≤2	22 (68.7%)	4 (12.5%)	24 (75%)	2 (6.3%)	0.098	0.532	23 (71.6%)	3 (9.4%)	0.424
>2	5 (15.6%)	1 (3.1%)	6 (18.7%)	0			5 (15.6%)	1 (3.1%)	
<i>MF Stage</i>									
<IIIB	14 (63.6%)	3 (13.6%)	15 (68.2%)	2 (9%)	0.675	0.589	14 (63.6%)	3 (13.6%)	0.675
≥IIIB	4 (18.2%)	1 (4.5%)	5 (22.7%)	0			4 (18.2%)	1 (4.5%)	
<i>mSWAT MF</i>	18 (81.8%)	4 (18.2%)	20 (90.9%)	2 (9%)	0.195	0.554	18 (81.8%)	4 (18.2%)	0.484
<i>Pruritus</i>									
Yes	15 (46.8%)	5 (15.6%)	18 (56.2%)	2 (6.3%)	0.007	0.010	16 (50%)	4 (12.5%)	0.003
No	12 (37.5%)	0	12 (37.5%)	0			12 (37.5%)	0	

Scores on the Skindex-29 were classified as mild/moderate (<44) or severe (≥44). For the DLQI, scores indicated no impact on quality of life (<11) or impact (≥11). On the HADS, scores were categorized as unlikely case (<10) or likely case (≥10) of anxiety/depression. Finally, for the WHO-5, scores suggested no impact on well-being (<13) or impact (≥13).


DLQI, Dermatology Life Quality Index; HADS, Hospital Anxiety and Depression Scale; MF, mycosis fungoides; mSWAT, Modified Severity-Weighted Assessment Tool.

believe this is due to the underrepresentation of non-MF PCLs in the sample. Some studies suggest that CTCLs have worse QOL vs CBCLs<sup>15</sup>; even so, this is an understudied area where more research is needed to clarify this issue.

The main limitations of the study were its cross-sectional design, which means that causal associations cannot be established due to lack of follow-up; the small sample size,

with a small proportion of non-MF PCLs; and the lack of a control group.

In conclusion, our study demonstrates that patients with PCLs experience an impact on their QOL, with pruritus being the most limiting factor in this regard. Since all that has been stated previously, and considering the chronic nature of this disease, along with the lack of a curative treatment, and



**Figure 1** Bivariate fit of Skindex-29 values with respect to ISS. A positive association is observed between ISS and Skindex-29 values ( $p < 0.001$ ; 95% CI, 0.908–1.922).

the impact on QOL suffered by patients, the development of a specific questionnaire for PCLs remains of paramount importance.

## Ethical considerations

This study was approved by the Provincial Ethics Committee for Research of Granada, in full compliance with the Declaration of Helsinki. Informed consent was obtained from participants, either verbally or in writing. The confidentiality of participant data was rigorously preserved, with an anonymous database used for analysis.

## Funding

None declared.

## Conflicts of interest

None declared.

## References

- WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet; beta version ahead of print]. WHO classification of tumours series, vol. 11, 5th ed. Lyon, France: International Agency for Research on Cancer; 2022.
- Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. *Blood*. 2019;133:1703–14.
- Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, Stonesifer C, Tensen CP, et al. Cutaneous T cell lymphoma. *Nat Rev Dis Primer*. 2021;7:61.
- Jonak C, Porkert S, Oerlemans S, Papadavid E, Molloy K, Lehner-Baumgartner E, et al. Health-related quality of life in cutaneous lymphomas: past, present and future. *Acta Derm Venereol*. 2019;99:640–6.
- Sampogna F, Frontani M, Baliva G, Lombardo GA, Alvetretti G, Di Pietro C, et al. Quality of life and psychological distress in patients with cutaneous lymphoma. *Br J Dermatol*. 2009;160:815–22.
- Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. *Cancer*. 2006;107:2504–11.
- Shinohara MM, Mahurin HM, Tarabadkar E, Hippe DS, Lachance K, Kim EJ, et al. Health-related quality of life in cutaneous T-cell lymphoma: a cross-sectional survey study. *Skin Health Dis*. 2021;1:e45.
- Rosenthal JM, Kim EJ. Health-related quality of life in cutaneous T-cell lymphoma: examining all sides of the issue. *Br J Dermatol*. 2020;182:20–1.
- Dalal M, Mitchell S, McCloskey C, Zagadailov E, Gautam A. The clinical and humanistic burden of cutaneous T-cell lymphomas

A. Sánchez-Merino, F. Vílchez-Márquez, A. Núñez-García et al.

- and response to conventional and novel therapies: results of a systematic review. *Expert Rev Hematol.* 2020;13:405–19.
10. Holahan HM, Farah RS, Fitz S, Mott SL, Ferguson NN, McKillip J, et al. Health-related quality of life in patients with cutaneous T-cell lymphoma? *Int J Dermatol.* 2018;57:1314–9.
11. Engin B, Keçici AS, Uzun AÖ, Yalçın M. Psychiatric comorbidity, depression, and anxiety levels and quality of life of the patients with mycosis fungoides. *Dermatol Ther.* 2020;33:e13922.
12. Semenov YR, Rosenberg AR, Herbosa C, Mehta-Shah N, Musiek AC. Health-related quality of life and economic implications of cutaneous T-cell lymphoma. *Br J Dermatol.* 2020;182:190–6.
13. Nguyen M, LeWitt T, Pang Y, Bagowski K, Espinosa ML, Choi J, et al. Lifestyle, demographic and Skindex measures associated with cutaneous T-cell lymphoma: a single institution cohort study. *Arch Dermatol Res.* 2023;315:275–8.
14. Ottevanger R, van Beugen S, Evers AWM, Willemze R, Vermeer MH, Quint KD. Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature. *J Eur Acad Dermatol Venereol.* 2021;35:2377–87.
15. Martinez XU, Chowdhury A, Stiller T, Palmer J, Loscalzo M, Barrios E, et al. The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum of cutaneous lymphomas. *Support Care Cancer.* 2021;29:6669–79.
16. Porkert S, Lehner-Baumgartner E, Valencak J, Knobler R, Riedl E, Jonak C. Patients' illness perception as a tool to improve individual disease management in primary cutaneous lymphomas. *Acta Derm Venereol.* 2018;98:240–5.
17. Navarro Matilla B, Ortiz Romero PL, Pujol Vallverdú RM, Combalia Escudero A, Zapata Paz I, González Barca E, et al. Cost of treating cutaneous T-cell lymphoma in Spain: analysis of MICADOS study data by disease Stage. *Actas Dermosifiliogr.* 2024;115:119–29 [article in English, Spanish].
18. Ottevanger R, van Beugen S, Evers AWM, Willemze R, Vermeer MH, Quint KD. Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator. *JAAD Int.* 2022;9:57–64.
19. Serrano L, Martinez-Escala ME, Zhou XA, Guitart J. Pruritus in cutaneous T-cell lymphoma and its management. *Dermatol Clin.* 2018;36:245–58.